Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Division of Pulmonary Medicine, Barzilai University Medical Center, Ashkelon, and Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Eur Cytokine Netw. 2024 Feb 1;35(1):13-19. doi: 10.1684/ecn.2024.0494.
COVID-19 vaccination and acute infection result in cellular and humoral immune responses with various degrees of protection. While most studies have addressed the difference in humoral response between vaccination and acute infection, studies on the cellular response are scarce. We aimed to evaluate differences in immune response among vaccinated patients versus those who had recovered from COVID-19. This was a prospective study in a tertiary medical centre. The vaccinated group included health care workers, who had received a second dose of the BNT162b2 vaccine 30 days ago. The recovered group included adults who had recovered from severe COVID-19 infection (<94% saturation in room air) after 3-6 weeks. Serum anti-spike IgG and cytokine levels were taken at entry to the study. Multivariate linear regression models were applied to assess differences in cytokines, controlling for age, sex, BMI, and smoking status. In total, 39 participants were included in each group. The mean age was 53 ±14 years, and 53% of participants were males. Baseline characteristics were similar between the groups. Based on multivariate analysis, serum levels of IL-6 (β=-0.4, p<0.01), TNFα (β=-0.3, p=0.03), IL-8 (β=-0.3, p=0.01), VCAM-1 (β=-0.2, p<0.144), and MMP-7 (β=-0.6, p<0.01) were lower in the vaccinated group compared to the recovered group. Conversely, serum anti-spike IgG levels were lower among the recovered group (124 vs. 208 pg/mL, p<0.001). No correlation was identified between antibody level and any of the cytokines mentioned above. Recovered COVID-19 patients had higher cytokine levels but lower antibody levels compared to vaccinated participants. Given the differences, these cytokines might be of value for future research in this field.
COVID-19 疫苗接种和急性感染会引起不同程度的细胞和体液免疫反应。虽然大多数研究都集中在疫苗接种和急性感染之间的体液反应差异上,但关于细胞反应的研究却很少。我们旨在评估接种疫苗的患者与从 COVID-19 中康复的患者之间免疫反应的差异。这是一项在三级医疗中心进行的前瞻性研究。接种组包括医护人员,他们在 30 天前接受了第二剂 BNT162b2 疫苗。康复组包括在 3-6 周后从严重 COVID-19 感染中康复(室内空气饱和度<94%)的成年人。在进入研究时,采集了血清抗刺突 IgG 和细胞因子水平。应用多元线性回归模型评估细胞因子的差异,控制年龄、性别、BMI 和吸烟状况。共有 39 名参与者被纳入每个组。平均年龄为 53±14 岁,53%的参与者为男性。两组间的基线特征相似。基于多变量分析,与康复组相比,接种组血清中 IL-6(β=-0.4,p<0.01)、TNFα(β=-0.3,p=0.03)、IL-8(β=-0.3,p=0.01)、VCAM-1(β=-0.2,p<0.144)和 MMP-7(β=-0.6,p<0.01)水平较低。相反,康复组的血清抗刺突 IgG 水平较低(124 与 208 pg/mL,p<0.001)。抗体水平与上述任何细胞因子之间均未发现相关性。与接种疫苗的参与者相比,康复的 COVID-19 患者的细胞因子水平更高,但抗体水平更低。鉴于这些差异,这些细胞因子可能对该领域的未来研究具有价值。